Your session is about to expire
← Back to Search
Monoclonal Antibodies
Group II: Ustekinumab 45 mg for Psoriasis
Phase 3
Waitlist Available
Research Sponsored by Centocor Research & Development, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 40 to week 52
Awards & highlights
Summary
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 40 to week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 40 to week 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12
Secondary outcome measures
Change in Dermatology Life Quality Index (DLQI) at Week 12
Psoriasis
Number of Participants With Physician Global Assessment (PGA) of Cleared or Minimal at Week 12
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group III: Ustekinumab 90 mgExperimental Treatment1 Intervention
Group II: Group II: Ustekinumab 45 mgExperimental Treatment1 Intervention
Group III: Group I: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ustekinumab
FDA approved
Ustekinumab
FDA approved
Find a Location
Who is running the clinical trial?
Centocor Research & Development, Inc.Lead Sponsor
4 Previous Clinical Trials
907 Total Patients Enrolled
1 Trials studying Psoriasis
766 Patients Enrolled for Psoriasis
Centocor, Inc. Clinical TrialStudy DirectorCentocor, Inc.
72 Previous Clinical Trials
30,214 Total Patients Enrolled
10 Trials studying Psoriasis
6,086 Patients Enrolled for Psoriasis
Share this study with friends
Copy Link
Messenger